<SEC-DOCUMENT>0001213900-14-000160.txt : 20140113
<SEC-HEADER>0001213900-14-000160.hdr.sgml : 20140113
<ACCEPTANCE-DATETIME>20140113070039
ACCESSION NUMBER:		0001213900-14-000160
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140110
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140113
DATE AS OF CHANGE:		20140113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52446
		FILM NUMBER:		14523167

	BUSINESS ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k011014_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
    <title>f8k011014_actiniumpharma.htm</title>
    <!--Licensed to: Edgar Efile-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported): January 10, 2014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-52446</font></div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">88-0378336</font></div>
</td>
</tr><tr>
<td valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of&#160;incorporation)</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">File Number)</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="66%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">501 Fifth Avenue, 3rd Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New York, NY</font></div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="32%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10017</font></div>
</td>
</tr><tr>
<td valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code: <font style="DISPLAY: inline; FONT-WEIGHT: bold">(646) 459-4201</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="78%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">N/A</font></div>
</td>
</tr><tr>
<td valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="DISPLAY: inline; TEXT-DECORATION: underline">see</font> General Instruction A.2. below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="73%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="73%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</font></div>
</td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="73%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: wingdings; FONT-SIZE: 10pt">o</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1.01&#160;&#160;&#160; Entry into a Material Definitive Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 10, 2014,&#160; Actinium Pharmaceuticals, Inc. (the "Company") conducted the final closing (the &#8220;Final Closing&#8221;) of its private placement of securities (the &#8220;Offering&#8221;) pursuant to a Unit Purchase Agreement, dated as of January 10, 2014 (the &#8220;Purchase Agreement&#8221;) and Subscription Agreement, dated as of January 10, 2014 (the &#8220;Subscription Agreement&#8221;), with certain accredited investors named therein (the &#8220;Investors&#8221;)&#160;&#160;pursuant to which: the Investors at the Final Closing agreed to purchase (i) an aggregate of 551,810 shares ( the &#8220;Shares&#8221;) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 137,952 &#160;shares of common stock at an exercise price of $9.00 per share (the &#8220;Warrants&#8221;).&#160;&#160;The Company received $3,310,860&#160;in gross proceeds from the sale of securities under the Purchase Agreement at the Final Closing, bringing the total gross proceeds received by the Company in the Offering to $6,636,720. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font>The aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As required by the&#160;&#160;Purchase Agreement, at the closing, the investors also became parties to the Registration Rights Agreement dated as of January 10, 2014 pursuant to which the Company will be required to register with the United States Securities and Exchange Commission such Shares and the shares of Common Stock underlying the Warrants (the &#8220;Warrant Shares&#8221;).&#160;&#160;If the registration statement is not filed or declared effective within the timeframe set forth in the Registration Rights Agreement, the Company is obligated to pay the investors an amount equal to 1% of the total purchase price of the securities per month (up to a maximum of 6% in the aggregate) until such failure is cured.&#160;&#160;Officers and directors of the Company also entered into a lock-up agreements pursuant to which they agreed not to sell or otherwise transfer any shares of Common Stock or other securities of the Company owned by them until the date that is 6 months following the effective date of the registration statement to be filed in connection with the offering.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Laidlaw &amp; Company (UK) Ltd., a FINRA registered broker dealer,&#160;acted as exclusive placement agent with respect to the Offering. In connection with the Final Closing, the placement agent received a cash fee of $331,086 and&#160;&#160;warrants to purchase 68,976 shares of common stock at an exercise price of $9.00 per share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A press release announcing the closing is filed herewith as Exhibit 99.1 and is incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">General Information</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The foregoing is not a complete summary of the terms of the&#160;transactions contemplated by the Purchase Agreement and reference is made to the complete text of the Purchase Agreement, Subscription Agreement,&#160;&#160;Registration Rights Agreement, Form of Warrant and Form of Lock Up Agreement which will be filed as exhibits to the Company&#8217;s Annual Report on Form 10-K for the year ended&#160;December 31, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The securities offered have not been registered for primary sale by the Company under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 3.02&#160;&#160;&#160; Unregistered Sales of Equity Securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information contained in Item 1.01 above is incorporated herein by reference in response to this Item 3.02.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Shares and Warrants described were offered and sold solely to &#8220;accredited investors&#8221; in reliance on the exemption from registration afforded by Rule 506 of Regulation D promulgated under Section 4(2) of the Securities Act.&#160;&#160;In connection with the sale of these securities, the Company relied on&#160;&#160;teach investor&#8217;s written representations that it was an "accredited investor" as defined in Rule 501(a) of Regulation D.&#160;&#160;In addition, neither the Company nor anyone acting on its behalf has offered or sold these securities by any form of general solicitation or general advertising.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Item 9.01&#160;&#160; &#160;Financial Statements and Exhibits</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(d) Exhibits</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exhibit No.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#cceeff">
<td align="left" valign="top" width="5%">
<div><a name="tabdatabeginip"><!--efplaceholder--></a>99.1</div>
</td>
<td align="left" valign="top" width="95%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Press Release of Actinium Pharmaceuticals, Inc. dated January 13, 2014.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated: January&#160;&#160;13, 2014</font></div>
</td>
<td align="left" colspan="2" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="47%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="47%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Kaushik J. Dave&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="47%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160;&#160;Kaushik J. Dave</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">3</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k011014ex99i_actinium.htm
<DESCRIPTION>PRESS RELEASE OF ACTINIUM PHARMACEUTICALS
<TEXT>
<html>
<head>
    <title>f8k011014ex99i_actinium.htm</title>
    <!--Licensed to: Edgar Agents-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="img01.jpg" alt=""></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.9pt" align="center"><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold"><font color="black" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt"><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">Actinium</font><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">&#160;</font><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">Pharmaceuticals,</font><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">&#160;</font><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">I</font><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">n</font><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">c</font><font color="black" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">.</font></font></font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Actinium Closes on Approximately $6.6 Million in Private Placement</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font color="black" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font color="black" style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Company completes its offering of common stock and warrants</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NEW YORK, NY &#8211; January 13, 2014</font> &#8211; Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that it has closed the final tranche of approximately $3,310,860 to bring total gross proceeds of approximately $6,636,720 million from the private placement of common stock and warrants to new and existing accredited investors (the &#8220;Offering&#8221;). The aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,700 in order to cover over-allotments. The proceeds of the Offering will be used primarily for further development of Iomab&#8482;-B, a Phase 3 clinical stage bone marrow conditioning agent for preparing patients for hematopoietic stem cell transplantation (HSCT) and Actimab-A, Actinium's lead drug candidate in multicenter Phase 1/2 trials in Acute Myeloid Leukemia (AML).</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">"This funding gives us additional capital to prepare for the pivotal trial Phase 3 trial of Iomab&#8482;-B as a potentially curative treatment regimen for elderly AML patients preparing for a bone marrow transplant,&#8221; said Kaushik J. Dave, President and CEO of Actinium. &#8220;In addition, we will continue the Phase 1/2 proof of concept trial of Actimab-B as an induction therapy for elderly AML.&#160;&#160;Both Iomab&#8482;-B and Actimab-A address areas of cancer treatment where there are no FDA approved medications".</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the terms of the Offering, the Company sold approximately 1,106,120 shares of common stock at $6.00 per share and issued 276,529&#160;five-year warrants exercisable at $9.00 per share.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Laidlaw &amp; Co. (UK) Ltd., a FINRA-registered broker dealer, acted as the exclusive placement agent with respect to the Offering.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The offer and sale of the securities have not been registered under the Securities Act of 1933, as amended, and the shares may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. The Company has agreed to file a registration statement covering the resale of the common stock and shares of common stock issuable upon exercise of the warrants issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The foregoing is not a complete summary of the terms of the transactions contemplated by the Purchase Agreement and reference is made to the complete text of the Purchase Agreement, Subscription Agreement, Registration Rights Agreement, Form of Warrant and Form of Lock Up which will be filed as exhibits to the Company's Annual Report on Form 10-K for the year ended December 31, 2013.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Actinium Pharmaceuticals</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.&#160;&#160;Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies.&#160;&#160;The Company&#8217;s lead radiopharmaceutical Iomab&#8482;-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.&#160;&#160;The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab&#8482;-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission.&#160;&#160;The company&#8217;s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial. For more information, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.actiniumpharmaceuticals.com</font>.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Iomab&#8482;-B</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Iomab&#8482;-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant which is the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission will include a single, pivotal Phase 3 clinical study if it is successful. The trial population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The study design of the pivotal trial is based on results of an earlier Phase 1/2 trial in which sixty percent of the older patients with refractory and relapsed AML exhibited disease free survival estimated at six months. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months. There are currently no treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab&#8482;-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to a bone marrow transplant in various blood cancers including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab&#8482;-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Iomab&#8482;-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine 131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Actimab-A</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actimab-A, Actinium's second program is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single arm multicenter trial. The Company expects to make significant progress in the Phase 2 portion of the trial and announce interim results in 2014. Actimab-A is being developed as a first line therapy and has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actimab-A consists of the Lintuzumab monoclonal antibody and actinium 225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Lintuzumab is the humanized version of M195 and is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. Both the alpha particle technology and lintuzumab were initially developed at Memorial Sloan Kettering Cancer Center.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For more information:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Visit our web site </font><font style="FONT-STYLE: italic; DISPLAY: inline; TEXT-DECORATION: underline">www.actiniumpharmaceuticals.com</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contact:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Investor/Media Relations: Corey Sohmer, (646) 459-4201</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Email: <font style="TEXT-DECORATION: underline">csohmer@actiniumpharmaceuticals.com</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Statement for Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="#000000" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This news release contains &#8220;forward-looking statements&#8221; as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.&#160;&#160;No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="#282726">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="#282726">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font color="#282726">3 </font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img01.jpg
<TEXT>
begin 644 img01.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`#P`
M?@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[^****`"BBC/\`G]/Y\4`!..:B,J;"[<(%+%FP%557<2S$[5`&
M<EB`,')`YK\,O^"DW_!:CX??L?ZUK_P-^".B:?\`&/\`:8TR"/\`MK3=2:_M
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M^7;!\#?B-K>D?\)/X0^`?Q2\3Z3>S7#/K_AWX0^-]:TR62$7"7LW]LV'@R\7
M5K6"T.RXNK?4AY,DTC)<P3PJ5V_AM\:/BO\``_6/[7^#WQ7^)GP?UWP]=.;*
MT\#>-M5\)7FF1W$49BTZ[\,7T4VF7>E07<5TDFG:]H=YI>KW'^DW5C&SO$L^
MT?9+YW_"R_,345]I_))KI_>\WYZ;'^H.I!&5'IV]LC^?\Q0YPI.,^W^>3^'_
M`->OY-O^"?W_``<(ZA)KWACX.?MY?V0@U^_M=)T7]I#PSIEMHNFZ->78@BL;
M/XS>$;(/::1;7D\T,/\`PG7AP6VG6<DA?7_#>F6$%QK8_I._:&_:.^%G[,GP
M<\3_`!P^*_B*#3?`_AK38[Q'L7@O-3\2W]ZF-%\/>%+,31_VSKFOW#Q6^DVM
MO)LE#FYGFALHKBYB[<!@\9F>-P>79=A<1C<PQ^(HX7!X3"TIUZ^)Q6(JQHT*
M%&E3YISJU:DU&$$KO?1-7Y<;C,+EN$Q.88[$4<)@<'2J8C%8O$5(T</0H48.
MI5JU:DVE"%*"O.3VNK79PG[8O[7WPK_8O^#>K?%WXG7,]V?..C>"O!>E-&WB
M/Q]XPGMY;C3_``WHL3_NX$,<,E]K.KW933M!TBVN=0O9"%AM[C\X/^"7W_!5
MO5?VM?&GB+X"_'G0++PK\<&NO$WC'P!/X=TF_M_"_BGP#'<R:F^@2QR*\VF>
M(?!&E7%M#_:6HK:V_B_11::PD=KJCW-BW\S7[1?[17[0_P#P4J_:4M-?FTK4
M-=U?Q%JUO\/_`(*?`?P[?7-S;^$[#7+FYNM(T+3/,A31I]9GT^Q&O?$7QE?2
M6$+11S7$UW::!HL,5KSWQ`^,>B?LZV3_``"_9:^(EJOQ)TWQ3IFH?M(_M0^#
M;V]M9_'?C_P9>Q:O8?"/X*Z_:^1"/@3\+/&L,4FNZA:R[_C)XUTAM5U0'P7I
MVE6=U_8''7A+X<^"_@Z\#Q[?-?&/BY8?%Y3@\!BO95N%I867,Z=VXQJ9;3I5
M:M',L1*G4CFV/E#"Y:Z4,`\?2_E[@_Q(X[\5/%6G7X,DLN\+^%W4PN:XO&8;
MVM+/95VO>4-'''UE"-3+HPJP^HX6,L3B_:5,0L/5_P!%6)@3\O`(SCCOSGCG
M#'D9]\58K\C/^"1/_!1/7/V^_@IK;^/_``A?Z#\8_@\^@>&OB7XDTK29H/AQ
MXZOM6L[JZTOQ%X6OEC%II^O7UG9->>,/!0(?PSJ%W#+9--HNJ::8OUR7.!GK
M7\:P^%;_`#WUU=_.[[L_JFSC[O;3OITU22V[*RV6B0M%%%4`4UF(Z#/3N!U.
M/T]>GO3JA=L.O!/W>GINQ_.A_JM+7O=VM;1^>FNG:X?=KHK[-]%TWV/CS7O^
M"AG[#_A?6];\-^(OVI_@CI&O^&]6O-"U_2+SQYHZ:AH^LZ=>2Z??Z;J%L)F>
MWN[*^@FM+J*3!@N(GBDVLIKX/_X*#?\`!7#X(?#;]F/QQ>_LG_&SX5_%#X^>
M)X!X1\!6OAWQ;IFJ1^"Y=:MKG^T_B1K$44N/LWA#28KJ]T:U<2#5?%DF@:28
M)X;JX5?Q$_:!_P""0/[6GCGX[?&_QEI?B_\`9EAT+Q9\8_B9XLT'3]5^/.G:
M=?0Z5XC\=:WK]O%JVFR:-YEA?I;7TDFH6?GF:RU$RQ)+L\V6OS#_`&F_V4OB
M5^R1XY\,^#?BMK_P_P!1U/Q+X<F\7Z?J'PR\:IXW\.II]KJ=Q8&WO-8M+"U.
MD:D+BP>2'2Y`V(C%>1W'S[4_NK*?H^?1UQN`R[$XOQTJX?%8G`8+$8K"\^54
M_JV)KX6E5Q&'YIX2=_8U9RI_%S>ZT[O4_D;,_&KQLP>-QE##^#ZK86ABL30P
M^*=3,9^WHTJTJ=*NE&,%^\@E.UFDW92DE<\'T?PEX[\?>+](M-1\7>'+#Q#X
MNU4KJ7C/X@>.H;3PY'X@US5/^)SXG\?^+;RZGOK"SNQOUSQ!XBN8;^YFNBT$
M-M+=2P0-_7%^PW\./^"-_P"QUX7\.:KXC_:._9[^-WQ^E2/4O$?Q?\:ZI8ZO
ML\07,"O=1_#KPK>17VE>#M%L5C^S6<]C;/XAFAB-UK&KRW+>5!_.'^RU^Q+\
M7_VPT\5W/PT\1?"RSA^'[^&K76+[XI>/)_A\NIQZ_;ZH]B-%FUG17_MT:)#H
M\UMJ!TA633;B:TAOY6:[B:OK0?\`!&3]K[$CR?$G]DQI&>-WF@_:(TP%01$%
M4BXT%PC0;8?LT<<L2841F81N0_55^CQ]&FG/_D^V)7+\:@LLJW>C;4EA9)M[
MKE@O\*V7%'QO\=Y1C)>#U*HG)VL\RO&.R3;JQ2=MW96U32LS^M63_@I]_P`$
M^[>VMYY/VN/@TEK,DGD2+XDPKK!(8I`!%:\%6`4)M1F#(T8V2(7\/\?V7_!+
M#_@J;)J'PJ?Q1\(?C-\1+/PUK6IZ-XD\!7":9\7_``7IL)@TV^\1>$_%\&G6
MVIVJ:9<ZG9>9;32ZCHMT]Q%%J6EWUI+)#+_,[J/_``1I_:CMD@@7XE_LB201
M1HD+WG[2.CVN9F99II;<-X2;RX!>W,MQ''M\Q\>1("KI*?T\_P""/_\`P3Y^
M.'[,?[7&J_$CXD^,_P!GK7M&E^#?C+PQ'IGPP^,5CXY\31ZAK/B'PG?1W,VA
M6NCZ=*NEI!ILBW.H,S1Q3S6\7DKYJ&OC^._!;P$X?X,S_/.&O%_&YYQ!E^#]
MME>3U(8%0QV)]K3C[&2I8"%3E]FYU')5J7+RKXN96^GX/\6?&'.N)LERK/O"
MZCDV38_&QH9CFG/B_:8'#\DI.K"%2M.,I<RA&S33C*3UL?SY?\%!?V`?BQ^P
M%\7KKX;^-8[GQ=\._%$6MZC\$/B_9:9]GT_Q]H`0K/IGB,6CII^D?$31%O&M
M_$.AW44S26RPZ[H%RVD7,4:_4O[)/Q]T7]KGX+Z7_P`$X/VM_B"VDQ^%KN?6
MOV*OVA/%VJQ6&C_"'XG:9H.J:;IWPA^)^JZI>00^+_ASXAM;C4-!\,:M=6MU
MK/A];VV\+P@R)X:O;/\`M>_:L_99^$7[8?P6\3_`_P",NA_VGX:UY!>:9JUE
M(+3Q+X*\46D<@T7QGX2U109=,\0Z)+-));RH?(OK62[TC4H;S2]0O+.X_P`Z
MG]J_]FWQA^RE\>OB%\`OB%JFF^*M:^']_#9VGBWP?<)=^&]8TV[CBU/PWJ*Q
MQR,^C:\UE>63>)?#&J+/J6EZHDEE';SP_9-0F_DO(L]S7AS.,KX@R+&U,!FN
M4XW#9C@,9A])TL71:G2J<LERU(RMRSIU%*G4IN=*<94YR4OZ/S?*<!GF5X[)
MLVP\<7EN8X:MA<9AZOO1GAZ\;35T_=<=)PG%IPJ)3BU)7/JSXC>(?#?[(7AG
MQ)^SI\/O'GA?Q9^UGXTDO_"'[47Q<\$7%_K'A?X2>#9[.2'7_P!FWX.^,88K
M17\3ZNL=KIGQG^(>E6L%[>6MQ/\`#OP]/'8V?B3[1Y+^P[^Q'\2_V\_C58_!
MOX5Z;'X7\"6-K:ZG\8?B=%975UIOPQ\)7DYA$<[7\>FG6?%6J#398/!WAWR]
M^IZF9-4U.X&DZ-JLA\$_9^^!?B?]H_XQ_"[X$^"-;\.>%_$?Q.\3Q:#HNM>-
M[P>&="CNI;F]NY[FXN>9M0N([`ZE<0Z):37=]KVJ-8:-81S:CJ%NQ_T8OV,?
MV/?A-^Q'\$-!^"WPN@NKV.">36_&_C76]DGBGXC>.;^&*/6O%_B292PCGO7B
M2WTS2;=AI^@Z1!9:1IZ"WM0\GH\6\8<0\>\0X[BCBG'3S+-\R5)U*TX.E2PU
M*$8_5\'A,.Y2CA<-AZ4HT</0H<E.G"E\/M)3D^'ACA?)>#<EP7#W#V"CE^6X
M%5%1HI7K59U*CJ5L1B:J;G6Q%:I+FJU*LI5)-I-J,8Q7I'[/'[/?PO\`V7OA
M)X.^"WP@\/P^'_!7@S38[.U79`VJZUJ$B1G5?$WB6_@@M_[8\3^(+M7U'6]6
MEB26ZNY"J)%:QP6\7MU%%?/'O!1110`5&Q^9<GC&<8]QD^H_K^=24A`/4`_4
M9H?RW6ZNK7UT?E^(:G\$G[2?_!+O]OSQI^T?\?\`QEX:_91^(&M>'O%GQO\`
MBSXB\/:TE]\/)++4=`UOQ]X@U71-5L([_P`9"\CMM1TV]M[Q(KF&V=/M+)):
MP-$4'R=\8?V$/VO?V>O!.H_$GXU?!#Q#\(_A]IEU8Z<?$OC+Q'\+]*T^>_U-
MWMK33(;?3O%-UJ&IZW?R>?+8Z;I%G>W4WSEX9(+:2X@_TB]B?W%_[Y'^%?+G
M[97[*/P^_;2_9Y^(?[/OQ$B%MIWC'2)3X?\`$]M:VUQJ_@3QI8J]SX5\;Z%Y
MZY34M`U58;AHXY(/[0L&O=*GE6UOI\_VIEOTY?$S*\!EV74.%.`9TLMP&"R^
MC.M@^(95*E'`X>EAJ<ZKAQ#3A[2<*2E/DA&"FVXP4;1/Y8QWT2^`L?C<9CJN
M?<74ZV-QE?&5%2QF5<D)XBK*K.%-5,HG:"E.2CS.4E&UY2E>3_SD?`_@/Q%\
M1O$_A7X9^$UT[Q1XR\3ZE:Z-X6\/S>*?!D,VJ^(-58BST/P_=:MKUMHT5[JL
MZ&-;;[9!=7^HS1106YGFCAE^U5_X).?\%"XW./V-/B4L4,?E1"/4?AJ\LD;K
M+&R.C>.#;1"$;V0)]H'^D*\1AF0N/BG]I_\`9D^*_P"Q_P#%G7/@1\:O"AT'
MQSI-P;S2=:T^YNK?0O%/AZTG$>B?$?P%J]Y#;2:AH&K/9PW'_$GNDUCPOK5B
MUCJD.F:C:&&;]^?V%O\`@X4\:_#S0-/^&'[97@7Q)\5M.\.Z7H^GZ+\8_AI%
M9:CX_CL+:RBMHK3Q_P"';RYT[2/%FHB"%+D^*K+5]$UB]Q,FK:7J&M//>/UO
MZ>7B;*5WPEX>I-W<5@^([\S>KNN)8_)66OX8Q^B'P"G_`,E%QG.5])2Q^6QY
M=MHPRN,7M:S23VT/S93_`())_P#!0@;]W['?Q#G:6%S<73S_``YBN7=FMT11
M%_PF[POL9-S[RRM#&CQPK("@_7?_`((N_L*?M4_LX_MAWOQ#^,_[//B_X8>#
MY?@EXW\--XCU>Z\(+IC^(M1\0^$+VVLA#H'B35;R9K^*PO9+3[7;!+=+4R"2
M)YVC?]3_``__`,%T?^"86N>&4\1R?M$OH;'3XM0GT#7_`(9_%"T\3V_F&"*:
MS_LRV\(WHO;ZTDG"7$>E7.H0E8IY[:>XM(C./@W]JS_@XS^#>@>&=6T7]COP
M'XB^*'C*X:>PTOXF?$O0KSP3\+-!'F0JVMIH5W+#X^\5.EK(;K3--FT;PW:W
M4ACDN[]+9#;S?)\=?3`X_P"/>$\\X0S+AO@O!9?GV!G@,3B,OPF?1QE&G.=.
M;GAI8KB#$T85.:E%7G1J+EE)65SW^%/HR\'\(\1Y1Q+@L]XJQ.+R?%PQE##X
M[%8&IA*M6"DHQKPI8"C)P]YZ1DGM:VM_J?\`X*[_`/!532_V+?"__"DO@Y):
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M)\D=$HKEC4FU!U(>]*/[OQ!G$<AR'-LYC@L7F?\`9F7XK&RP.`@ZF,Q,J%'V
MOL*4'9^^N:\HN;I4XN?+*24'_-=\>?@OXK_9R^*6M?#KXB:M;Q:QI%GH/B3P
M]KW@#7KC5?"?C'PQ(T]YI/Q&^%/C7P_=VO\`;7AS4[N"\ETO6+.2RN--\5VK
M:3?66E:OI5_#:?UY_P#!%W_@K?'^TII&B_LK_M+>*8)?VD/#NE3#P#\0=3N]
M/2#X_P#AC2HEDF66>VV6R_%?POIS0Q^)M.#F?Q18Q2>*;19+E-:BM?Y>?AKX
MN^&OQ'^&UI^S3\?=0@T/X8_VQJ&O_!#XUS6$FIO^S9\3-8OHWN]2?^S9)+[5
M?V>?'5P1-\7_``'8RNV@W$D7Q&\+6L.M66I6^J>!>+/A3\3?@C\5=2\%:]!+
M\.OBA\,-7M-=LM?\/:S;V$6BZW:"U\1>'/'W@/Q]93Z1'J/AS7[=-,\3>!O'
M7AZ\CGU[1;^WN[2U>,7=JWW_`(T>#G$?@WQ34R3-5+,<IQLL3B.'.(:5"%'#
M9U@:4H*5.,*3K1I9KAN>G',<%+$3E1]W$4W+#XBC.I\=X7^*&1^*.0+-\M?L
M,RI5(TLYR>357'9;C)2E*I4F]'/"UOWE6A5@^6I"#@U&I2DC_4M!SGV)%+7X
MZ_\`!'7_`(*'>)?VYO@QK.B?$SPUJMI\8_@C;>&O#_C_`,<V$*7OP_\`B7'J
MUG='1/%^D:Q86MOIFE>+=1ATRYD\8^"BD4FEWNS5],#Z)K%E':_L57Y(FI)-
M:IZI]UT?S6I^D>:U3VM?;IVW6H4444P"BBB@`I",XZ\?K[&EHH`^6_VK_P!C
M7]G?]M+X=M\.?V@_`%CXMTRT>YN?#?B*VD.D>./`^I74:PW&K>"?%]FJZQX<
MO9XDCCO5LY_L.IP11VVJV=];((:_EW^-_P#P;8?'7P7?:S>?LM?'GPGX]\%B
M9[O3/!OQ-34_`7Q(_L\1!VT27Q9X>AOO`OBFX+Q):6ESJNA^$+%%D,MXH91L
M_LLHI63UMKW`_P`^)O\`@BM_P4TTS5_[#N?V6HK]KB[-M:ZUH7Q?^%Y\+V?F
MR-+%JEU)<^*K>8QI&S&=XK&,R.%@DLE0QI'])_"'_@WC_;M\;7TP^+'BCX-?
M!71(+@K)/?:]>?$G7;Z(6Y2">T\/^"Q9Z61$;@J]O=>,=+M#+:HLVF:A$([F
M7^XJBE9_S/\`JW^7]:W'KO\`UM_DC\T/V$?^"5_[,_[",+^(_!.GW_C[XSZC
MI?\`9&O?&OQLL$_B:;3Y5B6[TGPKID.[2?`^AW?DQBZL]%0ZEJ"*L6LZQJD<
M-L(OTG>%0N02H7!`&!G!S@G:20>-W]X9!X8U8I&.`?\`/6J[/1M;/T:?K:ZO
M;8-]V]5R[MV6NB5]%J]%8_C[_P""R_\`P2M7X3ZCKW[77[./A?/PLU74[K6O
MCE\.M#TD74GPVU35+J>[U'XD^%[.$-*G@K6=1N6N/&&DVL13PM<O_:UC%'H%
MW>QZ5^>?[%OP1\1_\%"KKPC^R/J^GZ\VJ_#:S'B3X=?M#:=HVG^*#\$OAF^I
MF_\`%_PI^)$=]KFB+XF^#OB^[N'F^&.CV>H?\)1X!^(MR-1\-VMSX1U'Q+86
M/]_6H6MK?VMU8W]K;7UC?6UQ9WUC>01W-G>V=U%Y%S:7EM,KPW-M<02R0SP2
MH\4L;LCJ5)%?/G[.'[*GP&_9*\->)O!_P#\`:9X$T3Q3XJU3QKKL=H\]Y>7^
MK:U=7,Z6TNHWTD]\=%T&V*:3X7T8SFP\/Z1%'8:=%%&&+_T^_I"+B+P/S'PS
MX[X=_P!:LXP-3+J7!O$E?%.C5RNC>?U;$8^K&^+K9AE,(3I86M1ERYAAZOU7
M,N:E3F\3_/B\%?['\6\KXYX/SG_5W`8V&+Q'$N34:'-3Q[BX*I0PT$E1A0Q\
MZJJ5XU/]RJP=;!QO-0IZW[,/[-'PA_9(^#_A7X'_``4\,6_AKP;X7MF:1PJS
M:QXFUV["OK7C#Q7J@1)M9\3Z_=*;O4K^?Y4)CL;"*TTRSLK.W^A.GZ_KS5>`
MD@$DG(7.?^!G/UXJQ7\OQ5E:R2W25W9-75V]WU?F]-#^@]=4]XMQ=MFXMQ;^
+;75OU"BBBF!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
